Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to 19.88%.

  • Haemonetics' EBIT Margin rose 29500.0% to 19.88% in Q4 2025 from the same period last year, while for Dec 2025 it was 19.05%, marking a year-over-year increase of 59100.0%. This contributed to the annual value of 16.3% for FY2025, which is 37000.0% up from last year.
  • As of Q4 2025, Haemonetics' EBIT Margin stood at 19.88%, which was up 29500.0% from 17.87% recorded in Q3 2025.
  • Haemonetics' EBIT Margin's 5-year high stood at 21.58% during Q1 2025, with a 5-year trough of 9.41% in Q2 2021.
  • In the last 5 years, Haemonetics' EBIT Margin had a median value of 13.7% in 2022 and averaged 12.31%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -203100bps in 2021, then surged by 166500bps in 2022.
  • Haemonetics' EBIT Margin (Quarter) stood at 10.22% in 2021, then soared by 39bps to 14.18% in 2022, then fell by -4bps to 13.67% in 2023, then increased by 24bps to 16.94% in 2024, then grew by 17bps to 19.88% in 2025.
  • Its EBIT Margin was 19.88% in Q4 2025, compared to 17.87% in Q3 2025 and 16.76% in Q2 2025.